Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: Results of a national survey

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 5, 2006, Pages 655-668

  Chey, W D ^a,c   Eswaren, S ^a   Howden, C W ^b   Inadomi, J M ^a   Fendrick, A M ^a   Scheiman, J M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB; SUCRALFATE; VALDECOXIB;

ADULT; AGED; CARDIOTOXICITY; CARDIOVASCULAR RISK; COLON HEMORRHAGE; CONTINUING EDUCATION; CORONARY ARTERY DISEASE; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG COATING; DRUG SAFETY; DRUG SELECTIVITY; DRUG USE; DYSPEPSIA; ENTERIC COATED TABLET; FEMALE; GASTROENTEROLOGY; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HEART PROTECTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTERNAL MEDICINE; LOW DRUG DOSE; MALE; MEDICAL EDUCATION; NORMAL HUMAN; PAIN; PHYSICIAN; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SMALL INTESTINE HEMORRHAGE; STROKE; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; ATTITUDE OF HEALTH PERSONNEL; CARDIOTONIC AGENTS; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE SURVEYS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; PHYSICIANS, FAMILY; PRIMARY HEALTH CARE; PROTON PUMPS; RISK FACTORS;

EID: 33645016284     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02810.x     Document Type: Review

References (33)

1. Del Valle J Chey WD Scheiman JM Chapter 66: Acid-peptic disorders In Yamada T ed Textbook of Gastroenterology 4th edn Philadelphia, PA JM Lippincott 2003 1321 76
2. TM 2004 (January 2004-December 2004)q4.
3. Wolfe MM Lichtenstein DR Singh G Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs N Engl J Med 1999 340 1888 99
4. Peloso PM Scheiman JM The economic implications of COX-2 specific inhibitors Am J Med 2001 110 50S 4S
5. Bombardier C Laine L Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 2000 343 1520 8
6. Silverstein FE Faich G Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis JAMA 2000 284 1247 55
7. Goldstein JL Eisen GM Agrawal N et al. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib Aliment Pharmacol Ther 2004 20 527 38
8. Hippisley-Cox J Coupland C Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested cast-control analysis Br Med J 2005 330 1366 9
9. Lévesque LE Brophy JM Zhang B The risk of myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults Ann Intern Med 2005 142 481 9
10. Graham DY Agrawal NM Campbell DR et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs Arch Intern Med 2002 162 169 75
11. Chan FKL Hung LCT Suen BY et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial Gastroenterology 2004 127 1038 43
12. U.S. Preventive Services Task Force Aspirin for the primary prevention of cardiovascular events: recommendation and rationale Ann Intern Med 2002 136 157 60
13. Armstrong CP Blower AL Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration Gut 1987 28 527 32
14. Singh G Ramey DR Morfield D et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study Arch Intern Med 1996 156 1530 6
15. Scheiman JM Fendrick AM NSAIDs without a prescription: over-counter access, under counted risks Am J Gastroenterol 2002 97 2159 60
16. Hayden M Pignone M Phillips C et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. preventive services task force Ann Intern Med 2002 136 161 72
17. Weil J Colin-Jones D Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding Br Med J 1995 310 827 30
18. Derry S Loke YK Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis Br Med J 2000 321 1183 7
19. Lai KC Lam SK Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use N Engl J Med 2002 346 2033 88
20. Kelly JP Kaufman DW Jurgelon JM et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product Lancet 1996 348 1413 6
21. Laine L Maller ES Yu C et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial Gastroenterology 2004 127 395 402
22. Lanas A Garcia-Rodriguez LA Arroyo MT et al. Coxibs, NSAIDs, Aspirin, PPIs and the risks of upper GI bleeding in common clinical practice Gastroenterology 2005 128 A 94 abstract 629
23. Huang JQ Sridhar S Hunt RH Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis Lancet 2002 359 14 22
24. Campbell DR Haber MM Sheldon E et al. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine Am J Gastroenterol 2002 97 2208 14
25. Hawkey CJ Næsdal J Wilson I et al. Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs Gut 2002 51 336 43
26. Chan FKL To KF Wu JCY et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomized trial Lancet 2002 359 9 13
27. Lai KC Lam SK Chu CM et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users - a randomized trial Aliment Pharmacol Ther 2003 18 829 36
28. Saad R Chey WD A clinician's guide to the diagnosis and treatment of H. pylori Clev Clin J Med 2005 72 109 26
29. Fendrick AM Bandekar RR Chernew ME et al. Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis Arthritis Care Res 2002 47 36 43
30. Spiegel BMR Targownik L Dulai GS et al. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis Ann Intern Med 2003 138 795 806
31. Mukherjee D Nissen SE Topol EJ Risk of cardiovascular events associated with selective COX-2 inhibitors JAMA 2001 286 954 9
32. Lanas A Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract Aliment Pharmacol Ther 2004 20 321 31
33. American Medical Association Physicians in the United States and Possessions by Selected Characteristics Chicago c. 1995-2004 [updated 2004 Jun 24; cited 2004 Nov. 12]. Available at: